Morphic Medical announced the first commercial patient received treatment with its Reset therapy.
Boston-based Morphic develops Reset, an incision-free, endoscopically delivered therapy for treating metabolic disorders.
The duodenal-jejunal bypass liner (DJBL) is implanted and removed endoscopically, remaining in place for up to nine months. By creating a temporary barrier in the upper intestine it can support significant weight loss and blood sugar control. The company designed its offering to target the underlying cause in obesity and type 2 diabetes.
Related: Insight Medbotics unveils Glenn – a new MRI-compatible surgical robot
Morphic says the device enhances the natural gut hormone responses in a way similar to GLP-1 therapies. However, unlike gastric bypass surgery, it offers a minimally invasive, fully reversible option.
Doctors in London performed the first commercial procedure on Sept. 19 at Kings College Hospital NHS Foundation Trust. Dr. Bu’Hussain Hayee, the Trust’s clinical director for liver, endoscopy and gastroenterology, performed it.
Morphic Medical said it marks the first use of Reset outside of clinical trials, with the device offered as a standard treatment. According to a news release, the procedure took under 30 minutes to perform and proved successful without complication.
The case took place just weeks after the company shared positive findings from a study of Reset. Morphic’s study confirmed substantial and durable benefits with Reset. That includes an average of 18.9% total body weight lost. Blood sugar levels, as measured by HbA1c, fell by 1.3%, with the greatest improvements seen in patients starting at higher levels. The company saw durable benefits, with 77% of patients maintaining improvement three years after the removal of Reset.
Morphic currently holds CE mark for Reset and offers it in Germany now, too, with plans to expand across Europe.
“Treating our first commercial patient with RESET is a defining moment for Morphic,” Mike Gutteridge, president & CEO of Morphic Medical, said. It shows that what began as pioneering clinical research is now becoming a reality in everyday medical practice. Reset delivers substantial, durable improvements in both weight and blood sugar control, and does so through a safe, minimally invasive and fully reversible procedure that takes under thirty minutes to perform.
Other companies currently targeting the duodenum to address diabetes and obesity include Endogenex and Fractyl, among others.
